Evidence map›Paper›PMID 38484140›Full record

ArticleAging2024

Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.

Yong Wei, Mingxia Zhu, Ye Chen, Qianying Ji, Jun Wang, Luming Shen, Xin Yang, Haibin Hu, Xin Zhou, Qingyi Zhu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yong WeiDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
Mingxia ZhuDepartment of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Ye ChenThe First Medicine College, Taizhou Campus of Nanjing University of Traditional Chinese Medicine, Taizhou 225300, China.
Qianying JiDepartment of Urology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
Jun WangDepartment of Urology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
Luming ShenDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
Xin YangDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
Haibin HuDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
Xin ZhouDepartment of Oncology, The Affiliated Suqian First People’s Hospital of Nanjing Medical University, Suqian 223812, China.
Qingyi ZhuDepartment of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China.
Second Affiliated Hospital of Nanjing Medical University · CNJiangsu Province Hospital · CNFirst Affiliated Hospital of Soochow University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is a common malignancy in elderly men. We have applied Traditional Chinese Medicine CFF-1 in clinical treatments for PCa for several years. Here, we aimed to identify the underlying mechanism of CFF-1 on PCa using network pharmacology and experimental validation. Active ingredients, potential targets of CFF-1 were acquired from the public databases. Subsequently, protein-protein interaction (PPI) and the herbs-active ingredients-target network was constructed. A prognostic model for PCa was also constructed based on key targets.

Indexed as

Network PharmacologyProstatic NeoplasmsAgedHumansMaleMedicine, Chinese TraditionalMolecular Docking SimulationPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCFF-1network pharmacologyprognosisprostate cancerTraditional Chinese Medicine

Identifiers

PMID38484140
PMCPMC11006490
OpenAlexW4392751565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.